Gainers

• Zynex (NASDAQ:ZYXI) shares rose 7.1% to $0.32 during Friday's after-market session. The market value of their outstanding shares is at $8.5 million.
• PharmaCyte Biotech (NASDAQ:PMCB) stock rose 3.63% to $0.89. The market value of their outstanding shares is at $5.7 million. The company's, Q2 earnings came out yesterday.
• Kala Bio (NASDAQ:KALA) stock increased by 3.58% to $0.64. The company's market cap stands at $6.2 million.
• Genprex (NASDAQ:GNPX) shares increased by 3.28% to $2.2. The market value of their outstanding shares is at $4.9 million.
• Cue Biopharma (NASDAQ:CUE) stock rose 3.24% to $0.28. The company's market cap stands at $26.9 million.
• enVVeno Medical (NASDAQ:NVNO) shares increased by 3.12% to $0.33. The company's market cap stands at $7.0 million.

Losers

• Impact BioMedical (AMEX:IBO) shares declined by 17.5% to $0.54 during Friday's after-market session. The company's market cap stands at $5.4 million.
• Innate Pharma (NASDAQ:IPHA) stock decreased by 8.58% to $1.6. The market value of their outstanding shares is at $162.2 million.
• Scienture Holdings (NASDAQ:SCNX) stock fell 7.1% to $0.53. The market value of their outstanding shares is at $20.2 million.
• Wellgistics Health (NASDAQ:WGRX) stock decreased by 6.02% to $0.46. The company's market cap stands at $48.9 million.
• NeOnc Technologies Hldgs (NASDAQ:NTHI) stock declined by 6.0% to $6.59. The company's market cap stands at $136.7 million.
• NovaBay Pharmaceuticals (AMEX:NBY) shares decreased by 5.1% to $5.03. The company's market cap stands at $371.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.